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In vitro techniques are essential in elucidating biochemical mechanisms and for screening a
wide range of possible bioactive candidates. The number of papers published reporting in
vitro bioavailability and bioactivity of ﬂavonoids and ﬂavonoid-rich plant extracts is numer-
ous and still increasing. However, even with the present knowledge on the bioavailability
and metabolism of ﬂavonoids after oral ingestion, certain inaccuracies still persist in the lit-
erature, such as the use of plant extracts to study bioactivity towards vascular cells. There is
therefore a need to revisit, even question, these approaches in terms of their biological rele-
vance. In this review, the bioavailability of ﬂavonoid glycosides, the use of cell models for
intestinal absorption and the use of ﬂavonoid aglycones and ﬂavonoid-rich plant extracts
in in vitro bioactivity studies will be discussed. Here, we focus on the limitations of current
in vitro systems and revisit the validity of some in vitro approaches, and not on the detailed
mechanism of ﬂavonoid absorption and bioactivity. Based on the results in the review, there
is an apparent need for stricter guidelines on publishing data on in vitro data relating to the
bioavailability and bioactivity of ﬂavonoids and ﬂavonoid-rich plant extracts.
Flavonoid: Bioavailability: in vitro: Bioactivity: Plant extracts
Flavonoids belong to a large group of secondary plant
metabolites called polyphenols. They typically consist
of a 15-carbon skeleton consisting of two benzene
rings attached via a heterocyclic pyrane ring, labelled
as rings A, B and C, in a C6–C3–C6 arrangement.
Flavonoids occur either as glycosides, methylated deri-
vatives, bio-conjugates after phase I/II metabolism or
aglycones (the basic structure). The position of the B
ring may be at the C2-position in the case of most ﬂavo-
noids or in the C3-position in the case of isoﬂavones.
Common hydroxylation points are at positions 5, 7 (A
ring), 3′, 4′, 5′ (B ring), 3 and 2 (C ring). Differences
also depend on the presence of the C2 = C3 double
bond, and C4-ketone moiety. Fig. 1 shows the basic
structures and common classes of ﬂavonoids(1,2). They
are widely available in plant foods, such as Brassica
vegetables, onions, fruits and its derivatives like wines
and juices.
In nature, ﬂavonoids, except for ﬂavan-3-ols, generally
occur as glycosides of, most commonly, single units or
polymers or hexose, pentose, rhamnose, arabinose and/
or their combinations(3). These glycosidic moieties are
mostly attached to free hydroxyl groups in the A and C
rings via a β-glycosidic bond. For instance, ﬂavonols,
such as quercetin and kaempferol, are more commonly
found as 3-O-glycosides (although 7-O, 3,7-di-O, and
B-ring glycosidation also occur in some plants), while
7-O-glycosides are more common for ﬂavones, ﬂava-
nones and isoﬂavones(4). Flavonoids may also occur as
C-glycosides, wherein the glycoside moiety is directly
attached to the aglycone backbone via an acid-resistant
C–C bond. C-glycosylation mostly occurs at the C6 and
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C8 positions
(3). Flavonoid-C-glycosides however are not
as common as their O-glycoside counterparts and have
received much less attention in the literature(5).
In a survey conducted between 1999 and 2005, adults
from fourteen European countries (n 30 000) consumed
an average of 428 mg ﬂavonoids/d(6), while a study on
US adults reported an average consumption of 345 mg/
d(7). For both populations, ﬂavan-3-ols from tea consti-
tute most of the ﬂavonoid intake, followed by ﬂavanones,
ﬂavonols and anthocyanins, ﬂavones and isoﬂavones(6–8).
A survey of the 100 richest sources of polyphenols per-
formed using the online database Phenol-Explorer(9)
showed that fruit and vegetables, such as berries and arti-
choke, contain the most polyphenols per serving and are
composed of anthocyanins and ﬂavonols(10). Food in
general contains much more ﬂavonoid glycosides com-
pared with their aglycone counterparts(4). Flavonoid gly-
cosides, especially ﬂavonol and isoﬂavone glycosides, are
also generally stable under cooking conditions(11,12).
Results from epidemiological studies revealed that con-
sumption of ﬂavonoid-rich foods has been associated with
a reduced risk of death from CHD(13) and other chronic dis-
eases such as cancer, asthma and diabetes(14). These results
attracted thousands of in vitro assays to elucidate the bio-
activity of ﬂavonoids, including anti-oxidative(15,16), anti-
hypertensive(17), anti-obesity(18,19) anti-viral, hepatoprotec-
tive and immune-regulatory activities(20), among many
others. This has also sparked the interest of several research
groupsworldwide to screen for bioactive plants, which could
potentially provide these health-promoting effects, based on
their ﬂavonoid contents.
Bioavailability of ﬂavonoid glycosides
Although epidemiological studies report health-promoting
beneﬁts upon chronic consumption of ﬂavonoid-rich
foods, the underlying mechanisms behind these effects
are difﬁcult to ascertain because of their poor bioavail-
ability in vivo(21) due to factors such as food matrix inter-
actions, food processing, host (human)-related factors
(e.g. age, occurrence of certain diseases, lifestyle), and
most importantly the bioconversion (microbial, phase
I/II metabolism) of ﬂavonoids(22). Therefore, it is es-
sential to ﬁrst ensure that ﬂavonoids present in the plant
matrices being studied survive the digestion process and
are absorbed by the intestine. Once these conditions are
met, only then should potential bioactivity towards
enzymes, cells and tissues in the body be investigated.
For instance, while earlier studies have demonstrated
that quercetin glycosides are found intact in plasma, it
is now generally accepted that such compounds are in
fact absent from plasma after nutritional doses(23).
Upon reaching the epithelium, ﬂavonoid-O-glycosides
are hydrolyzed by either lactase phloridzin hydrolase
(LPH), cystolic β-glucosidase, or microbial hydrolases
Fig. 1. Basic structure of the common classes of ﬂavonoids and the common points of
glycosylation. Common glycosylation points are C3 and C7 (black arrows). B ring
glycosylation is also observed in some plants (hollow arrow). C-glycosides are least found
in plants (arrow with dotted lines).
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into aglycones. This deglycosylation step has been found
to be a critical step in the absorption and metabolism of
ﬂavonoid glycosides from the diet in human subjects(24).
LPH is a brush-border enzyme in small intestinal
cells that has a substrate speciﬁcity for ﬂavonoid-O-
β-glucosides(4) to release aglycones, which can then
passively diffuse through epithelial cells due to their lipo-
philicity(25,26). Dietary ﬂavonoids and isoﬂavone glyco-
sides are typically hydrolysed by LPH(27). Alternatively,
it has been earlier suggested that cystolic β-glucosidase
hydrolyses glycosides intracellularly when they are trans-
ported in the intestinal cells by sodium-dependent glu-
cose transporter 1 (SGLT1)(28). Both LPH and cystolic
β-glucosidase are expressed by the Caco-2 cell line and
ex vivo human small intestinal samples(29). However,
β-glucosidase activity in Caco-2 cells is much lower com-
pared with actual intestinal tissue samples(4,24).
Previously, ﬂavonoid deglycosylation and metabolism
has been thought to only occur via microbial metabol-
ism. However, it has been refuted as more and more evi-
dence suggests that ﬂavonoid glycosides can be absorbed
in the small intestine, as described earlier. Exemptions to
this however are ﬂavonoid rhamnosides, which need to
be metabolised by the bacteria due to the inability to
metabolise rhamnose(23,30,31).
Once intracellular, phase I and II metabolism converts
these aglycones into, commonly, glucuronides, sulphates
and methyl-esters, which are then either excreted to the
blood or efﬂuxed back to the lumen by ATP-binding cas-
sette transporters. The efﬂuxed metabolites and
unabsorbed ﬂavonoids are then passed on to the large
intestines, where microbial metabolism occurs that con-
vert them back to aglycones and eventually into smaller
phenolic acid metabolites(22). Blood from the intestines is
then directed to the liver, which metabolizes ﬂavonoids
that escaped the ﬁrst-pass metabolism. Therefore, circu-
lating ﬂavonoids are almost exclusively glucuronides >
sulphates >methyl-esters (in this order of abun-
dance)(31,32). These biotransformations along with the
role of efﬂux transporters signiﬁcantly reduce the bio-
availability of ﬂavonoids. In fact, although ﬂavonoid
intake reaches >300 mg/d, the concentration of total
ﬂavonoid metabolites that reach systemic circulation
does not exceed 5 µM after an oral dose challenge(23).
This is very important, as this concentration is mostly
insufﬁcient to drive a physiologically relevant bioactivity.
Use of Caco-2 cells as model for intestinal transport of
ﬂavonoid glycosides
Human colorectal adenocarcinoma Caco-2 cells have
been used in in vitro studies as an intestinal model for
more than 30 years. The cell line was developed by the
Sloan-Kettering Institute for Cancer Research(33). The
use of Caco-2 cells to simulate human intestinal absorp-
tion grew as more and more evidence suggested that drug
transport in human subjects in vivo is highly correlated to
the apparent permeability values measured using Caco-2
cells for certain drugs, such as ranitidine HCl, metoprolol
tartrate, piroxicam(34), minoxidil(35), naproxen,
antipyrine and metoprolol(36). These drugs however are
known to diffuse passively both in Caco-2 cells and
human intestinal tissue, thus implying that Caco-2 per-
meability data are rather correlated to passive diffusion
and not for actively transported drugs. Caco-2 cell per-
meability however was found to be 79- and 27-fold
lower for the hydrophilic slowly-passively transported
drugs terbutaline and atenolol, respectively. The carrier-
mediated transport rates of L-dopa, L-leucine and
D-glucose were also much slower in Caco-2 cells than
in human jejunum. These data indicate that Caco-2
cells are useful to predict passive intestinal transport of
molecules in human intestines, but is not a good model
for the transport of hydrophilic and actively transported
molecules, such as ﬂavonoid glycosides. This has been
attributed to the lack of transporter and enzyme expres-
sion in Caco-2 cell lines compared with the real human
intestinal epithelium(36). For instance, the LPH is
expressed in Caco-2 cells but its expression is much
lower compared with ex vivo intestinal samples(24). Due
to this, the metabolism of ﬂavonoid glycosides in vitro
is usually underestimated. In the previous study, kaemp-
ferol glucuronides and sulphates were not found at the
basal compartment of a Caco-2 Transwell® set-up upon
treatment with a kaempferol glycoside-rich cauliﬂower
leaf extract(37). In vivo, consumption of kaempferol
glycoside-rich endive resulted in the appearance of
kaempferol glucuronide in plasma(38). Glucuronides
and sulphates of ﬂavonoids were also not observed
after transport analysis of Xi-aochaichu-tang (a
Chinese herbal remedy) using Caco-2 cells(39).
Conversely, while it is now accepted that quercetin glyco-
sides do not exist in blood, Caco-2 cell transport experi-
ments of quercetin glucosides show basolateral transport
of these glycosides(40,41), which could be misinterpreted
as being bioavailable. Quercetin metabolites (glucuro-
nides, especially) were not observed when treating
Caco-2 cells with quercetin-3-glucoside in contrast to
treatment with quercetin aglycones. It therefore appears
that pre-deglycosylation during in vitro intestinal diges-
tion could enhance the intestinal conversion and meta-
bolic conversion of dietary quercetin glucosides(42).
The mechanism of absorption of ﬂavonoid glycosides
in intestinal cells is controversial. Many reports claim
that SGLT1 participates in the cellular uptake of quer-
cetin glycosides from the diet. It has been previously
shown that ﬂavonoid glycosides can be transported
across intestinal cells by the SGLT1 when there is no
efﬁcient uptake by passive diffusion(43). However, contra-
dictory results regarding the involvement of SGLT1 in
ﬂavonoid intestinal transport exist and thus require fur-
ther elucidation. For instance, while it was previously
reported that quercetin-3-glucoside is taken up across
the intestinal cells by SGLT1 in rat small intestines(44),
using SGLT1-expressing Xenopus laevis oocytes showed
that neither quercetin, luteolin, apigenin, naringenin,
pelarginidin, daidzein, genistein, nor any of their glycosy-
lated derivatives are substrates of this transporter(45).
Whether SGLT1 plays a role in ﬂavonoid glycoside
uptake or not, it is undoubtedly accepted that deglycosy-
lation exists extracellularly in the intestines and that
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effective deglycosylation is a critical step for ﬂavonoid
glycoside absorption. Therefore, the passive diffusion of
the liberated aglycone still remains the more efﬁcient
route of absorption, indicating that the participation of
SGLT1, if present, is less important.
The lack of LPH expression was previously addressed
by treating in vitro digested shallots and onions with lac-
tase (300 units, 37°C, 20 min) before adding to Caco-2
cells. In this study, quercetin absorption of lactase-
treated quercetin glycosides increased 14-fold in Caco-2
cells, indicating that lactase treatment could be a good
additional step for in vitro intestinal absorption stud-
ies(46). Given the importance of deglycosylation on ﬂavo-
noid glycoside absorption, the use of Caco-2 cell models
for intestinal transport without prior deglycosylation
steps should be re-evaluated. Steps for deglycosylation
after in vitro digestion, i.e. addition of lactase or LPH
to the digesta, should be considered prior to Caco-2
transport analysis.
Use of ﬂavonoid aglycones in in vitro bioactivity assays
A previous study on the angiotensin-I-converting enzyme
inhibitory activity of ﬂavonoids suggested that the IC50
(concentration needed to reduce angiotensin-I-converting
enzyme activity by 50 %) of ﬂavonoids fall within the
range 0·4–9·3 mM(47), which is substantially more than
the concentration of ﬂavonoids found in the blood.
Moreover, the compounds used in this study were agly-
cones and not phase I/II metabolites that are normally
found in the blood. The use of ﬂavonoid aglycones, with-
out regard to their bioavailability and metabolism has
been rampant and still growing rapidly. In 2002, questions
on the use of ﬂavonoid aglycones in in vitro systems to test
bioactivity was raised(31). In this review, the validity of
papers that reported in vitro bioactivity of high doses of
ﬂavonoids aglycones was questioned. Although it is accur-
ate to say that many studies used aglycones in much
higher doses than plasma concentrations, recent evidence
on the in situ deglucuronidation of ﬂavonoid glucuronides
during inﬂammation suggest that ﬂavonoid aglycones may
indeed exist locally in some tissues at concentrations
higher than found in the blood(48).
We have also shown previously that cells accumulate
ﬂavonoids differently under normal and stressed condi-
tions. Methyl-quercetin was found to accumulate more
in valinomycin-stressed cells than in unstressed undiffer-
entiated Caco-2 cells treated with quercetin. More inter-
estingly, quercetin and its methyl-ester derivative were
found on the cell membrane of the unstressed cells,
whereas they localised intracellularly upon exposure to
valinomycin, which caused a recovery in cellular viability
and reduction of intracellular reactive oxygen species(49).
These results are interesting as they point to the possibil-
ity that local/in situ concentrations of ﬂavonoids (in the
affected cells) could be much higher than the concentra-
tion of the metabolites in the blood. Unfortunately, no
comparative study on the local tissue concentration of
ﬂavonoids of healthy v. unhealthy subjects has been
reported. However, a previous study on the effect of
quercetin supplementation on the blood pressure of
stage I hypertensive men compared with normotensive
men reported that quercetin supplementation signiﬁcantly
reduced the blood pressure of hypertensive men that is
independent of changes in angiotensin-I-converting enzyme
activity, endothelin-I or nitric oxide plasma levels(50).
What is most interesting in the study is that plasma con-
centrations of normotensive men reached 2·3 (SD 1·8) µM,
whereas plasma concentration only reached 0·6 (SD 0·4)
µM at 10 h post administration for hypertensive men. It
could be possible that the difference in plasma concentra-
tions is caused by local accumulation of quercetin in
damaged cells (i.e. vascular cells), which caused the
reduction of blood pressure in the hypertensive group.
Given the earlier arguments, it is worth asking whether
the dose in in vitro bioactivity assays be limited to the
concentration of ﬂavonoid metabolites in the blood. If
an average person has about 5 litres blood and if indeed
deglucuronidation occurs locally, the concentration of
ﬂavonoid aglycones at the site of deglucuronidation
(i.e. point of inﬂammation) will be more than the concen-
tration in the blood as a whole. Further, the use of agly-
cones in in vitro assays may in fact be valid for some
cases. Unfortunately, it is currently not established
whether ﬂavonoids are indeed accumulating selectively
in damaged tissues and in what form they are present
(aglycones or methyl-conjugates). Thus, studies on the
concentration of ﬂavonoids and their corresponding
form in localised tissues merits further investigation.
Use of ﬂavonoid-rich plant extracts for bioactivity assays
Even with the growing evidence on the limited (even the
absence of) bioavailability of ﬂavonoid glycosides and
the present understanding of ﬂavonoid absorption and
bioactivity, the number of papers published reporting
the in vitro bioactivity of ﬂavonoid-rich plant extracts
in cellular models is very high and growing.
For instance, a recent study demonstrated that super-
critical CO2 extract of spent hop (Humulus lupulus L.),
which is dominantly composed of ﬂavanols (procyanidin
dimers) and ﬂavonols (quercetin and kaempferol glyco-
sides, including rhamnosides) reduced ADP-induced
platelet aggregation, in a concentration-dependent man-
ner when the plant extract was added to both whole
blood and platelet-rich plasma of both healthy volunteers
and patients with coronary artery disease(51). In this
study however, the plant extracts were directly mixed
with the blood samples at a concentration ranging from
1·5–15 µg gallic acid equivalents (GAE)/ml blood. The
effect was only observed in coronary artery disease
patients when >7 µg GAE/ml was used. Further,
human umbilical vein endothelial cells were also exposed
to the plant extract to assess cellular viability and anti-
platelet activity(51). However, the data presented would
have had more relevance if the bioavailability of the iden-
tiﬁed compounds in the plant extract was tested.
Although an in vivo test was performed, the authors
did not analyse the concentration and form of the ﬂavo-
noids that reached the blood. Based on the present
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knowledge on the bioavailability of ﬂavonoid glycosides,
it is clear that: (a) the total concentration of phenolic
metabolites in blood after a ﬂavonoid-rich diet would
not reach 1·5 µg GAE/ml blood and (b) ﬂavonoids in
blood after consumption of ﬂavonoid-rich foods do not
occur as glucosides and deﬁnitely not rhamnosides.
In another study, lotus (Nelumbo nucifera) extract,
41·8 mg quercetin equivalents/g (ﬂavonoid proﬁle not
reported) was applied to human umbilical vein endothe-
lial cells at a concentration range 10–100 µg GAE/ml cul-
ture medium to study its effect against endothelial
dysfunction, speciﬁcally vascular endothelial growth
factor-induced angiogenesis(52). Also, artichoke extract
(1–100 µg GAE/ml) was shown to inhibit inducible nitric
oxide synthase expression when directly applied to
human coronary artery smooth muscle cells(53). Lotus
and artichoke have however been previously reported
to contain mostly quercetin glucoside and glucuro-
nide(54), and luteolin rutinoside and glucoside(55), respect-
ively. Curly kale (Brassica oleracea L. convar. acephala
var. sabellica) extract was also recently reported to
reduce TNF-α induced neutrophil adhesion to human
umbilical vein endothelial cells via 24-h pre-incubation
of the human umbilical vein endothelial cells with curly
kale extract(56). Curly kale has been previously reported
to contain mostly highly glycosylated kaempferol and
quercetin(57).
The effect of a ﬂavonoid glycoside-rich extract of a
traditional Chinese medicine, semen astragali complanati
(Astragalus complanatus R.Br.) on the activation of nat-
ural killer-92 cells, a model for natural killer cells found
in the blood that combats tumours, was investigated by
incubating natural killer-92 cells with 12–200 µg (unspe-
ciﬁed whether GAE or per dry weight)/ml semen astrag-
ali complanati extract for up to 72 h(58). Apart from
problems relating to concentration and the type of ﬂavo-
noids present in these extracts, the clearance of polyphe-
nols in the blood was also not considered as ﬂavonoid
metabolites do not persist in circulation for 72 h when
using a single dose(59).
It is surprising that although ﬂavonoid glycoside
metabolism and bioavailability has been described in
many papers dating decades back, very recent papers
still do not consider bioavailability and metabolism of
ﬂavonoid glycosides as important considerations when
assessing in vitro bioactivity. There is therefore a need
for stricter acceptance rules or guidelines in reporting in
vitro bioactivity of ﬂavonoid-rich plant extracts, or any
plant extracts, in the literature. This does not only
include research data but also papers reviewing the bio-
activity of these plant extracts. For instance, a recent
review(60) reported the in vitro bioactivity of several
plant extracts on various cancer stem cells. Comments
on neither the identity of the active compound nor the
bioavailability of these plant components were however
made.
Recently, guidelines and recommendations in report-
ing requirements for bioactive components, such as ﬂavo-
noids have been published(61,62). In both guidelines, the
bioavailability of the ﬂavonoids in question should be
strictly considered when planning and reporting results
from in vitro experiments. According to Somoza
et al(61), studies should address ﬁve focus areas when
reporting in vitro bioactivity of plant-based bioactive
components: (1) Identiﬁcation of the active molecule/s
using state-of-art spectrometric and spectroscopic techni-
ques; (2) Quantitation of the active components using
validated methods; (3) Demonstration of the bioavail-
ability of the bioactive component using relevant in
vitro or in/ex vivo models; (4) Unequivocal identiﬁcation
and quantitation of metabolites generated in the bio-
availability study; (5) Mechanistic study using the rele-
vant compound.
Many papers, both recent and old, usually pass the
ﬁrst two criteria but generally fail to satisfy the third
and fourth. Instead, many jump to the mechanistic
study of the compounds found in the plant extract; skip-
ping the bioavailability and metabolism criteria. By fol-
lowing these criteria, the relevance of the data
published in literature will be preserved. The implemen-
tation of this entails a consensus among scientists and
publishers to increase the quality standard for publishing
data.
Conclusion
In this review, we have shown that current in vitro sys-
tems and approaches need to be reevaluated. There is
clearly a need to improve in vitromodels for bioavailabil-
ity, especially for ﬂavonoid glycosides. The analysis of
ﬂavonoid accumulation in speciﬁc tissues during inﬂam-
mation or stressed conditions offers a new line of
research. Finally, the bioavailability of ﬂavonoids from
plant extracts need to be strictly considered when plan-
ning in vitro experiments and elucidating their bioactivity
towards cellular models, such as vascular cells.
Acknowledgements
The author would like to thank the Belgian Nutrition
Society, Prof John Van Camp, Prof Katleen Raes and
Prof Guy Smagghe for the technical support. Special
thanks also go to Evelien Van Rymenant and Senem
Kamiloglu for proofreading the manuscript.
Financial Support
None.
Conﬂict of Interest
None.
Authorship
The author had sole responsibility for all aspects of prep-
aration of this paper.
Flavonoids and ﬂavonoid-rich plant extracts 179
P
ro
ce
ed
in
gs
o
f
th
e
N
u
tr
it
io
n
So
ci
et
y
https://doi.org/10.1017/S0029665116002858
Downloaded from https://www.cambridge.org/core. Universiteit Gent, on 27 Sep 2017 at 11:17:53, subject to the Cambridge Core terms of use, available at https://www.cambridge.org/core/terms.
References
1. Kumar S & Pandey AK (2013) Chemistry and biological
activities of ﬂavonoids: an overview. Scientiﬁc World J
2013, 16.
2. Dai J & Mumper RJ (2010) Plant phenolics: extraction,
analysis and their antioxidant and anticancer properties.
Molecules 15, 7313–7352.
3. Cuyckens F & Claeys M (2004) Mass spectrometry in the
structural analysis of ﬂavonoids. J Mass Spectrom 39, 1–15.
4. Day AJ, DuPont MS, Ridley S et al. (1998)
Deglycosylation of ﬂavonoid and isoﬂavonoid glycosides
by human small intestine and liver β-glucosidase activity.
FEBS Lett 436, 71–75.
5. Xiao J, Capanoglu E, Jassbi AR et al. (2016) Advance on
the ﬂavonoid C-glycosides and health beneﬁts. Critical Rev
Food Sci Nutr 56, S29–S45.
6. Vogiatzoglou A, Mulligan AA, Lentjes MAH et al. (2015)
Flavonoid intake in European adults (18 to 64 years).
PLoS ONE 10, e0128132.
7. Bai W, Wang C & Ren C (2014) Intakes of total and
individual ﬂavonoids by US adults. Int J Food Sci Nutr
65, 9–20.
8. Chun OK, Chung SJ & Song WO (2007) Estimated dietary
ﬂavonoid intake and major food sources of U.S. adults. J
Nutr 137, 1244–1252.
9. Rothwell JA, Perez-Jimenez J, Neveu V et al. (2013)
Phenol-explorer 3·0: a major update of the phenol-explorer
database to incorporate data on the effects of food process-
ing on polyphenol content. Database: J Biol Databases
Curation 2013, bat070.
10. Perez-Jimenez J, Neveu V, Vos F et al. (2010) Identiﬁcation
of the 100 richest dietary sources of polyphenols: an appli-
cation of the Phenol-Explorer database. Eur J Clin Nutr 64,
S112–S120.
11. Coward L, Smith M, Kirk M et al. (1998) Chemical mod-
iﬁcation of isoﬂavones in soyfoods during cooking and pro-
cessing. Am J Clin Nutr 68, 1486S–1491S.
12. Price KR, Bacon JR & Rhodes MJC (1997) Effect of stor-
age and domestic processing on the content and compos-
ition of ﬂavonol glucosides in Onion (Allium cepa). J
Agric Food Chem 45, 938–942.
13. Hertog MGL, Feskens EJM, Hollman PCH et al. (1993)
Dietary antioxidant ﬂavonoids and risk of coronary heart-
disease – the zutphen elderly study. Lancet 342, 1007–1011.
14. Knekt P, Kumpulainen J, Jarvinen R et al. (2002)
Flavonoid intake and risk of chronic diseases. Am J
Clinical Nutr 76, 560–568.
15. Pietta P-G (2000) Flavonoids as antioxidants. J Nat
Products 63, 1035–1042.
16. Fiol M, Adermann S, Neugart S et al. (2012) Highly glyco-
sylated and acylated ﬂavonols isolated from kale (Brassica
oleracea var. sabellica) – structure–antioxidant activity
relationship. Food Res Int 47, 80–89.
17. Balasuriya N & Rupasinghe HPV (2012) Antihypertensive
properties of ﬂavonoid-rich apple peel extract. Food Chem
135, 2320–2325.
18. Hsu CL & Yen GC (2008) Phenolic compounds: evidence
for inhibitory effects against obesity and their underlying
molecular signaling mechanisms. Mol Nutr Food Res 52,
53–61.
19. Kamiloglu S, Grootaert C, Capanoglu E et al. (2016)
Anti-inﬂammatory potential of black carrot (Daucus carota
L.) polyphenols in a co-culture model of intestinal Caco-2
and endothelial EA.hy926 cells. Mol Nutr Food Res (In
the Press).
20. Middleton E, Kandaswami C & Theoharides TC (2000) The
effects of plant ﬂavonoids on mammalian cells: implications
for inﬂammation, heart disease, and cancer. Pharmacol Rev
52, 673–751.
21. Manach C, Scalbert A, Morand C et al. (2004)
Polyphenols: food sources and bioavailability. Am J
Clinical Nutr 79, 727–747.
22. D’Archivio M, Filesi C, Vari R et al. (2010) Bioavailability
of the polyphenols: status and controversies. Int J Mol Sci
11, 1321–1342.
23. Manach C, Williamson G, Morand C et al. (2005)
Bioavailability and bioefﬁcacy of polyphenols in
humans. I. Review of 97 bioavailability studies. Am J
Clinical Nutr 81, 230S–242S.
24. Németh K, Plumb GW, Berrin J-G et al. (2003)
Deglycosylation by small intestinal epithelial cell
β-glucosidases is a critical step in the absorption and
metabolism of dietary ﬂavonoid glycosides in humans.
Eur J Nutr 42, 29–42.
25. Crozier A, Del Rio D & Clifford MN (2010)
Bioavailability of dietary ﬂavonoids and phenolic com-
pounds. Mol Aspects Med 31, 446–467.
26. Liu Y & Hu M (2002) Absorption and metabolism of
ﬂavonoids in the Caco-2 cell culture model and a perfused
rat intestinal model. Drug Metab Dispos 30, 370–377.
27. Kroon PA, Clifford MN, Crozier A et al. (2004) How
should we assess the effects of exposure to dietary polyphe-
nols in vitro? Am J Clin Nutr 80, 15–21.
28. Day AJ, Canada FJ, Diaz JC et al. (2000) Dietary
ﬂavonoid and isoﬂavone glycosides are hydrolysed by the
lactase site of lactase phlorizin hydrolase. Febs Lett 468,
166–170.
29. Nemeth K, Plumb GW, Berrin JG et al. (2003)
Deglycosylation by small intestinal epithelial cell beta-
glucosidases is a critical step in the absorption and metab-
olism of dietary ﬂavonoid glycosides in humans. Eur J Nutr
42, 29–42.
30. Chang HK, Shin MS, Yang HY et al. (2006) Amygdalin
induces apoptosis through regulation of Bax and Bcl-2
expressions in human DU145 and LNCaP prostate cancer
cells. Biol Pharm Bull 29, 1597–1602.
31. Williamson G (2002) The use of ﬂavonoid aglycones in in
vitro systems to test biological activities: based on bioavail-
ability data, is this a valid approach? Phytochem Rev 1,
215–222.
32. Walle T (2004) Absorption and metabolism of ﬂavonoids.
Free Radical Biol Med 36, 829–837.
33. Mahraoui L, Rousset M, Dussaulx E et al. (1992)
Expression and localization of Glut-5 in Caco-2 cells,
human small-intestine, and colon. Am J Physiol 263,
G312–G318.
34. Polli JE & Ginski MJ (1998) Human drug absorption
kinetics and comparison to Caco-2 monolayer permeabil-
ities. Pharm Res 15, 47–52.
35. Lowenthal DT & Affrime MB (1980) Pharmacology and
pharmacokinetics of minoxidil. J Cardiovas Pharmacol 2,
Suppl. 2, S93–S106.
36. Lennernäs H, Palm K, Fagerholm U et al. (1996)
Comparison between active and passive drug transport in
human intestinal epithelial (caco-2) cells in vitro and
human jejunum in vivo. Int J Pharm 127, 103–107.
37. Gonzales GB, Smagghe G, Mackie A et al. (2015) Use of
metabolomics and ﬂuorescence recovery after photobleach-
ing to study the bioavailability and intestinal mucus diffu-
sion of polyphenols from cauliﬂower waste. J Funct Foods
16, 403–413.
G. B. Gonzales180
P
ro
ce
ed
in
gs
o
f
th
e
N
u
tr
it
io
n
So
ci
et
y
https://doi.org/10.1017/S0029665116002858
Downloaded from https://www.cambridge.org/core. Universiteit Gent, on 27 Sep 2017 at 11:17:53, subject to the Cambridge Core terms of use, available at https://www.cambridge.org/core/terms.
38. DuPont MS, Day AJ, Bennett RN et al. (2004) Absorption
of kaempferol from endive, a source of kaempferol-3-
glucuronide, in humans. Eur J Clin Nutr 58, 947–954.
39. Dai J-Y, Yang J-L & Li C (2008) Transport and metabol-
ism of ﬂavonoids from Chinese herbal remedy Xiaochaihu-
tang across human intestinal Caco-2 cell monolayers.
Acta Pharmacol Sin 29, 1086–1093.
40. Walgren RA, Walle UK & Walle T (1998) Transport of
quercetin and its glucosides across human intestinal epithe-
lial caco-2 cells. Biochem Pharm 55, 1721–1727.
41. Boyer J, Brown D & Liu RH (2004) Uptake of quercetin
and quercetin 3-glucoside from whole onion and apple
peel extracts by caco-2 cell monolayers. J Agri Food
Chem 52, 7172–7179.
42. Murota K, Shimizu S, Chujo H et al. (2000) Efﬁciency of
absorption and metabolic conversion of quercetin and its
glucosides in human intestinal cell line Caco-2. Arch
Biochem Biophys 384, 391–397.
43. Jin X, Yi L, Chen M-L et al. (2013) Delphinidin-
3-glucoside protects against oxidized low-density
lipoprotein-induced mitochondrial dysfunction in vascular
endothelial cells via the sodium-dependent glucose trans-
porter SGLT1. PLoS ONE 8, e68617.
44. Walgren RA, Lin JT, Kinne RKH et al. (2000) Cellular
uptake of dietary ﬂavonoid quercetin 4 ‘-beta-glucoside
by sodium-dependent glucose transporter SGLT1. J
Pharmacol Exp Ther 294, 837–843.
45. Kottra G & Daniel H (2007) Flavonoid glycosides are not
transported by the human Na+/glucose transporter when
expressed in Xenopus laevis oocytes, but effectively inhibit
electrogenic glucose uptake. J Pharm Exp Therap 322,
829–835.
46. Boyer J, Brown D & Liu RH (2005) In vitro digestion and
lactase treatment inﬂuence uptake of quercetin and
quercetin glucoside by the Caco-2 cell monolayer.Nutr J 4, 1.
47. Al Shukor N, Van Camp J, Gonzales GB et al. (2013)
Angiotensin-converting enzyme inhibitory effects by plant
phenolic compounds: a study of structure activity relation-
ships. J Agric Food Chem 61, 11832–11839.
48. Perez-Vizcaino F, Duarte J & Santos-Buelga C (2012) The
ﬂavonoid paradox: conjugation and deconjugation as key
steps for the biological activity of ﬂavonoids. J Sci Food
Agric 92, 1822–1825.
49. Gonzales GB, Smagghe G, Vissenaekens H et al. (2016)
Quercetin mitigates valinomycin-induced cellular stress
via stress-induced metabolism and cell uptake. Mol Nutr
Food Res 60, 972–980.
50. Larson A, Witman MAH, Guo Y et al. (2012) Acute,
quercetin-induced reductions in blood pressure in
hypertensive individuals are not secondary to lower plasma
angiotensin-converting enzyme activity or endothelin-1:
nitric oxide. Nutr Res 32, 557–564.
51. Luzak B, Golanski J, Przygodzki T et al. (2016) Extract
from spent hop (Humulus lupulus L.) reduces blood plate-
let aggregation and improves anticoagulant activity of
human endothelial cells in vitro. J Func Foods 22, 257–269.
52. Lee JS, Shukla S, Kim J-A et al. (2015) Anti-angiogenic
effect of nelumbo nucifera leaf extracts in human umbilical
vein endothelial cells with antioxidant potential. PLoS
ONE 10, e0118552.
53. Xia N, Pautz A, Wollscheid U et al. (2014) Artichoke,
cynarin and cyanidin downregulate the expression of indu-
cible nitric oxide synthase in human coronary smooth mus-
cle cells. Molecules 19, 3654–3668.
54. Chen S, Wu B-H, Fang J-B et al. (2012) Analysis of ﬂavo-
noids from lotus (Nelumbo nucifera) leaves using high
performance liquid chromatography/photodiode array
detector tandem electrospray ionization mass spectrometry
and an extraction method optimized by orthogonal design.
J Chromatogr A 1227, 145–153.
55. Negro D, Montesano V, Grieco S et al. (2012) Polyphenol
compounds in artichoke plant tissues and varieties. J Food
Sci 77, C244–C252.
56. Kuntz S & Kunz C (2014) Extracts from Brassica oleracea
L. convar. acephala var. sabellica inhibit TNF-alpha sti-
mulated neutrophil adhesion in vitro under ﬂow conditions.
Food Func 5, 1082–1090.
57. Olsen H, Aaby K & Borge GIA (2009) Characterization
and quantiﬁcation of ﬂavonoids and hydroxycinnamic
acids in Curly Kale (Brassica oleracea L. Convar. acephala
Var. sabellica) by HPLC-DAD-ESI-MSn. J Agric Food
Chem 57, 2816–2825.
58. Han R, Wu W-Q, Wu X-P et al. (2015) Effect of total
ﬂavonoids from the seeds of Astragali complanati on nat-
ural killer cell function. J Ethnopharmacol 173, 157–165.
59. Hollman PCH (2004) Absorption, bioavailability, and
metabolism of ﬂavonoids. Pharm Biol 42, 74–83.
60. Pistollato F, Giampieri F & Battino M (2015) The use of
plant-derived bioactive compounds to target cancer stem
cells and modulate tumor microenvironment. Food Chem
Toxicol 75, 58–70.
61. Somoza V, Molyneux RJ, Chen Z-Y et al. (2015)
Guidelines for research on bioactive constituents – a jour-
nal of agricultural and food chemistry perspective. J
Agric Food Chem 63, 8103–8105.
62. Balentine DA, Dwyer JT, Erdman JW et al. (2015)
Recommendations on reporting requirements for ﬂavo-
noids in research. Am J Clin Nutr 101, 1113–1125.
Flavonoids and ﬂavonoid-rich plant extracts 181
P
ro
ce
ed
in
gs
o
f
th
e
N
u
tr
it
io
n
So
ci
et
y
https://doi.org/10.1017/S0029665116002858
Downloaded from https://www.cambridge.org/core. Universiteit Gent, on 27 Sep 2017 at 11:17:53, subject to the Cambridge Core terms of use, available at https://www.cambridge.org/core/terms.
